Existing players

Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), T2 Biosystems (TTOO), and Thermo Fisher Scientific’s (TMO) subsidiary TREK Diagnostics Systems.

What’s the Competitive Landscape for Accelerate Diagnostics?

However, only Becton Dickinson, bioMeriux, and TREK have products on the market that perform the antibiotic susceptibility test (or AST). According to Accelerate Diagnostics, none of its competitors’ products provide AST results as quickly as its Accelerate Pheno System.

Bruker’s Biotyper System

Additionally, Quantmatrix and Lifescale are in the process of developing competing products. Bruker’s Biotyper system based on mass spectrometry and in particular Matrix-assisted laser desorption ionization time of flight version (or MALDI-TOF) is a major competitor to Accelerate’s products. Bruker has entered a number of distribution agreements for its product. MALDI-TOF systems have a major price advantage in the market.

The U.S. Food and Drug Administration (or FDA) granted marketing approval for Accelerate Diagnostics’ Accelerate Pheno system and Accelerate Pheno Test BC kit for identifying and antibiotic susceptibility testing of pathogens directly from positive blood culture samples.

National Institute of Health grant

Accelerate Diagnostics received a $5 million grant from the National Institute of Health to develop a fast and reliable identification and categorical susceptibility test of carbepenem-resistant enterobacteriaceae directly from whole blood.

Arizona Commerce Authority

Accelerate Diagnostics entered a grant agreement with the Arizona Commerce Authority in August 2012 under which Accelerate was granted certain state and county sponsored incentives to relocate its headquarters to and expand its business within Arizona. Under the agreement, the authority agreed to a grant of $1 million to Accelerate to advance its project. Accelerate Diagnostics makes up about 0.02% of the Vanguard Health Care ETF’s (VHT) total portfolio holding.

In the next part of the series, we take a look at the financial performance of Accelerate Diagnostics.

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.